Etripamil shows promise. Because it is a nasal spray, etripamil allows rapid absorption into the body much faster than a tablet. Etripamil is not yet available on the market; however, several studies have demonstrated its effectiveness and safety, so it may be available in the near future.
If approved, we believe that etripamil nasal spray will be a valuable treatment option for patients suffering from PSVT. The NDA for etripamil
NODE-301 – ETRIPAMIL NASAL SPRAY FOR ACUTE TERMINATION OF SPONTANEOUS EPISODES OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (NODE-301 – etripamil
In an industry-funded trial, etripamil nasal spray was superior to placebo for rapid conversion of SVT, safe, and well tolerated.
Etripamil significantly improved PSVT -related symptoms. Satisfaction and effectiveness of at-home, nasal spray therapy for PSVT were higher for etripamil than placebo. Etripamil tended to reduce need for emergency room medical interventions for PSVT. These data support continued development of etripamil
El etripamil intranasal es un bloqueante de los canales de calcio de administración intranasal Referencia. Etripamil Nasal Spray for Rapid
A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular
PubMed journal article: Efficacy of etripamil nasal spray for acute conversion of supraventricular tachycardia: a network meta-analysis.
Milestone Pharmaceuticals announced that the FDA has accepted the company's NDA for Cardaymyst etripamil nasal spray for the treatment of paroxysmal
Comments